Additionally, based on the IPS scores, the immunotherapy efficacy of PD-1 inhibitors or CTLA4 inhibitors could be enhanced when combined with anti-CD93 therapy in STAD. The gene discussed is CD93; the disease is gastric adenocarcinoma.